LXRX Stock Analysis: Buy, Sell, or Hold?
LXRX - Lexicon Pharmaceuticals, Inc.
$2.24
0.08 (3.70%)
▲
5d:
+14.87%
30d:
+3.7%
90d:
+30.23%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.6/10
Get Alerted When LXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LXRX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: LXRX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: LXRX is currently trading at $2.24, which is considered slightly high relative to its 30-day fair value range of $1.91 to $2.17.
Technical Outlook: Technically, LXRX is in a strong uptrend. The price is approaching resistance at $2.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: LXRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.77 (+74.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LXRX is in a strong uptrend. The price is approaching resistance at $2.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: LXRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.77 (+74.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.91 -
$2.17
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 74.5% below Wall St target ($3.77)
Trading Range Analysis
30-Day Trading Range
$1.91 -
$2.17
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.84
Resistance Level
$2.24
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.47
Wall Street Target
$3.77
(+74.5%)
Revenue Growth (YoY)
1572.1%
Earnings Growth (YoY)
-63.4%
Profit Margin
-37.5%
Share & Embed Analysis
Last updated: June 24, 2026 11:44 AM ET
Data refreshes hourly during market hours. Next update: 12:44 PM
Data refreshes hourly during market hours. Next update: 12:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LXRX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Raymond Debbane
BUY
2000 shares
2026-02-25
Raymond Debbane
BUY
100000 shares
2026-02-23
Raymond Debbane
BUY
100000 shares
2026-02-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |